14.04.2011 • News

Sanofi Weighing Options For U.S. Dermatology Unit

Sanofi-Aventis said it was considering "strategic alternatives" for its U.S. dermatology business, as it seeks to refocus its business on growth areas such as diabetes and cancer treatments.

The company's comment came after Bloomberg News published a story on Wednesday on how Sanofi was seeking to sell the unit, which the report said could be valued around €300 million.

Sanofi has said previously that its dermatology business could come under review because it was too small. It does not disclose sales for the unit.

Sanofi

Virtual Event

CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Interview

Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.